Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9

Orosomucoid 1 (ORM1) has been shown to be upregulated in the serum of breast cancer patients; however, the expression and function of ORM1 in breast cancer remains unknown. We measured the expression of ORM1 in breast cancer tissues and cell lines using qRT-PCR. A colony formation assay was done to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luo Qiong, Jun Yin
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	orosomucoid 1 (orm1) epirubicin matrix metalloproteinases-2 (mmp-2) matrix metalloproteinases-9 (mmp-9) akt erk breast cancer Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/91d7bfa04d144769a59270eb84d96a51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:91d7bfa04d144769a59270eb84d96a51
record_format	dspace
spelling	oai:doaj.org-article:91d7bfa04d144769a59270eb84d96a512021-11-04T15:51:53ZOrosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 92165-59792165-598710.1080/21655979.2021.1987067https://doaj.org/article/91d7bfa04d144769a59270eb84d96a512021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.1987067https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987Orosomucoid 1 (ORM1) has been shown to be upregulated in the serum of breast cancer patients; however, the expression and function of ORM1 in breast cancer remains unknown. We measured the expression of ORM1 in breast cancer tissues and cell lines using qRT-PCR. A colony formation assay was done to assess cell proliferation and Transwell and wound healing assays were performed to determine the migration and invasion capacity of the cells, respectively. In addition, a CCK-8 assay was used to measure epirubicin cytotoxicity and western blot assays were done to analyze the putative mechanisms of epirubicin sensitivity. We found that the expression of ORM1 was upregulated in breast cancer tissues and cell lines. The expression of ORM1 enhanced the proliferation and migration of the cell lines. In contrast, down-regulation of ORM1 inhibited the expression of MMP-2 and MMP-9 and activation of the AKT/ERK signaling pathway. Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.Luo QiongJun YinTaylor & Francis Grouparticleorosomucoid 1 (orm1)epirubicinmatrix metalloproteinases-2 (mmp-2)matrix metalloproteinases-9 (mmp-9)akterkbreast cancerBiotechnologyTP248.13-248.65ENBioengineered, Vol 12, Iss 1, Pp 8822-8832 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	orosomucoid 1 (orm1) epirubicin matrix metalloproteinases-2 (mmp-2) matrix metalloproteinases-9 (mmp-9) akt erk breast cancer Biotechnology TP248.13-248.65
spellingShingle	orosomucoid 1 (orm1) epirubicin matrix metalloproteinases-2 (mmp-2) matrix metalloproteinases-9 (mmp-9) akt erk breast cancer Biotechnology TP248.13-248.65 Luo Qiong Jun Yin Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
description	Orosomucoid 1 (ORM1) has been shown to be upregulated in the serum of breast cancer patients; however, the expression and function of ORM1 in breast cancer remains unknown. We measured the expression of ORM1 in breast cancer tissues and cell lines using qRT-PCR. A colony formation assay was done to assess cell proliferation and Transwell and wound healing assays were performed to determine the migration and invasion capacity of the cells, respectively. In addition, a CCK-8 assay was used to measure epirubicin cytotoxicity and western blot assays were done to analyze the putative mechanisms of epirubicin sensitivity. We found that the expression of ORM1 was upregulated in breast cancer tissues and cell lines. The expression of ORM1 enhanced the proliferation and migration of the cell lines. In contrast, down-regulation of ORM1 inhibited the expression of MMP-2 and MMP-9 and activation of the AKT/ERK signaling pathway. Therefore, ORM1 may represent a potential therapeutic target for breast cancer and promote epirubicin resistance by regulating the expression of MMP-2 and MMP-9, as well as activating the AKT/ERK signaling pathway.
format	article
author	Luo Qiong Jun Yin
author_facet	Luo Qiong Jun Yin
author_sort	Luo Qiong
title	Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
title_short	Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
title_full	Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
title_fullStr	Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
title_full_unstemmed	Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
title_sort	orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/91d7bfa04d144769a59270eb84d96a51
work_keys_str_mv	AT luoqiong orosomucoid1promotesepirubicinresistanceinbreastcancerbyupregulatingtheexpressionofmatrixmetalloproteinases2and9 AT junyin orosomucoid1promotesepirubicinresistanceinbreastcancerbyupregulatingtheexpressionofmatrixmetalloproteinases2and9
_version_	1718444728400216064

Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9

Ejemplares similares